102 related articles for article (PubMed ID: 9854719)
41. Three-stage contingent screening for Down syndrome.
Wright D; Bradbury I; Cuckle H; Gardosi J; Tonks A; Standing S; Benn P
Prenat Diagn; 2006 Jun; 26(6):528-34. PubMed ID: 16634118
[TBL] [Abstract][Full Text] [Related]
42. [Second trimester Down syndrome serum screening--results from a pilot study].
Dimitrova V; Chernev T; Kremenski I; Mazneĭkova V; Mikhaĭlova E; Simeonov E; Tincheva R; Toncheva D
Akush Ginekol (Sofiia); 2002; 41(2):3-12. PubMed ID: 12066548
[TBL] [Abstract][Full Text] [Related]
43. Prenatal screening for Down syndrome: the problem of recurrent false-positives.
Wald NJ; Huttly WJ; Rudnicka AR
Prenat Diagn; 2004 May; 24(5):389-92. PubMed ID: 15164416
[TBL] [Abstract][Full Text] [Related]
44. [Trisomy 21 screening: value of ultrasound and serum markers in a combined approach].
Senat MV; Rozenberg P; Bernard JP; Ville Y
J Gynecol Obstet Biol Reprod (Paris); 2001 Feb; 30(1):11-27. PubMed ID: 11240502
[No Abstract] [Full Text] [Related]
45. Second-trimester Down syndrome maternal serum screening in twin pregnancies: impact of chorionicity.
Muller F; Dreux S; Dupoizat H; Uzan S; Dubin MF; Oury JF; Dingeon B; Dommergues M
Prenat Diagn; 2003 Apr; 23(4):331-5. PubMed ID: 12673641
[TBL] [Abstract][Full Text] [Related]
46. Integrated serum screening for Down syndrome in primary obstetric practice.
Knight GJ; Palomaki GE; Neveux LM; Smith DE; Kloza EM; Pulkkinen AJ; Williams J; Haddow JE
Prenat Diagn; 2005 Dec; 25(12):1162-7. PubMed ID: 16231402
[TBL] [Abstract][Full Text] [Related]
47. Comparison of nuchal translucency measurement and mid-gestation serum screening in assisted reproduction versus naturally conceived singleton pregnancies.
Maymon R; Dreazen E; Rozinsky S; Bukovsky I; Weinraub Z; Herman A
Prenat Diagn; 1999 Nov; 19(11):1007-11. PubMed ID: 10589049
[TBL] [Abstract][Full Text] [Related]
48. Repeat maternal serum testing in multiple marker Down's syndrome screening programmes.
Cuckle H; Densem J; Wald N
Prenat Diagn; 1994 Jul; 14(7):603-7. PubMed ID: 7526366
[TBL] [Abstract][Full Text] [Related]
49. Clinical application of inhibin a measurement: prenatal serum screening for Down syndrome.
Lambert-Messerlian GM; Canick JA
Semin Reprod Med; 2004 Aug; 22(3):235-42. PubMed ID: 15319826
[TBL] [Abstract][Full Text] [Related]
50. Combined test + inhibin A at week 13 in contingent sequential testing: an interesting alternative for first-trimester prenatal screening for Down syndrome.
Ramos-Corpas DJ; Santiago JC
Prenat Diagn; 2008 Sep; 28(9):833-8. PubMed ID: 18661488
[TBL] [Abstract][Full Text] [Related]
51. Combined ultrasound biometry, serum markers and age for Down syndrome risk estimation.
Bahado-Singh RO; Oz AU; Gomez K; Hunter D; Copel J; Baumgarten A; Mahoney MJ
Ultrasound Obstet Gynecol; 2000 Mar; 15(3):199-204. PubMed ID: 10846774
[TBL] [Abstract][Full Text] [Related]
52. Medically assisted reproduction and second-trimester maternal serum marker screening for Down syndrome.
Muller F; Dreux S; Lemeur A; Sault C; Desgrès J; Bernard MA; Giorgetti C; Lemay C; Mirallié S; Beauchet A;
Prenat Diagn; 2003 Dec; 23(13):1073-6. PubMed ID: 14691995
[TBL] [Abstract][Full Text] [Related]
53. Second-trimester maternal serum screening for Down syndrome in Mainland China.
Liao C; Huang Y; Li D; Song S; Yi C; Zhou J
Prenat Diagn; 2006 Dec; 26(13):1271-2. PubMed ID: 17139699
[No Abstract] [Full Text] [Related]
54. Age-specific detection and false-positive rates: an aid to counseling in Down syndrome risk screening.
Reynolds TM; Nix AB; Dunstan FD; Dawson AJ
Obstet Gynecol; 1993 Mar; 81(3):447-50. PubMed ID: 7679788
[TBL] [Abstract][Full Text] [Related]
55. Dual analyte screening for fetal Down syndrome in pregnant women over 35 years of age.
Cavalli P; Gnocchi E; Pennacchio A; Morrica B
Prenat Diagn; 1998 Jun; 18(6):637-8. PubMed ID: 9664616
[No Abstract] [Full Text] [Related]
56. Value of maternal serum unconjugated oestriol measurement in prenatal screening for Down's syndrome.
Wald NJ; Kennard A; Watt HC; Smith D
Prenat Diagn; 1994 Aug; 14(8):699-706. PubMed ID: 7527536
[TBL] [Abstract][Full Text] [Related]
57. Maternal serum alpha-fetoprotein and dimeric inhibin A detect aneuploidies other than Down syndrome.
Wenstrom KD; Chu DC; Owen J; Boots L
Am J Obstet Gynecol; 1998 Oct; 179(4):966-70. PubMed ID: 9790380
[TBL] [Abstract][Full Text] [Related]
58. Logistic regression generated probability estimates for trisomy 21 outcomes from serum alpha fetoprotein and beta human chorionic gonadotrophin: simplification with increased specificity.
Evans MI; Chick L; O'Brien JE; Dvorin E; Johnson MP; Krivchenia E; Sokol RJ
J Matern Fetal Med; 1996; 5(1):1-6. PubMed ID: 8796757
[TBL] [Abstract][Full Text] [Related]
59. Urinary screening tests for fetal Down syndrome: I. Fresh beta-core fragment.
Cole LA; Rinne KM; Mahajan SM; Oz UA; Shahabi S; Mahoney MJ; Bahado-Singh RO
Prenat Diagn; 1999 Apr; 19(4):340-50. PubMed ID: 10327140
[TBL] [Abstract][Full Text] [Related]
60. Levels of urinary beta-core fragment, total oestriol, and the ratio of the two in second-trimester screening for Down syndrome.
Kellner LH; Canick JA; Palomaki GE; Neveux LM; Saller DN; Walker RP; Osathanondh R; Bombard AT
Prenat Diagn; 1997 Dec; 17(12):1135-41. PubMed ID: 9467810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
